Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (611) Arrow Down
Filter Results: (611) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (1,026)
    • People  (4)
    • News  (257)
    • Research  (611)
    • Events  (9)
    • Multimedia  (24)
  • Faculty Publications  (398)

Show Results For

  • All HBS Web  (1,026)
    • People  (4)
    • News  (257)
    • Research  (611)
    • Events  (9)
    • Multimedia  (24)
  • Faculty Publications  (398)
← Page 6 of 611 Results →
Sort by

Are you looking for?

→Search All HBS Web
  • 12 Dec 2022
  • Research & Ideas

Buy-In from Black Patients Suffers When Drug Trials Don’t Include Them

Black patients and their doctors may be more open to new medications if drug trials included more Black people, new research shows. Currently, Black Americans represent just 5 percent of drug trial... View Details
Keywords: by Scott Van Voorhis; Pharmaceutical; Health
  • June 2020
  • Case

Breakthroughs at Blueprint Medicines

By: Richard G. Hamermesh, Kathy Giusti and Susie L. Ma
Precision medicine company Blueprint Medicines was building a successful track record for bringing drug therapies to market 40% faster than average. The company had spent $40 million dollars and two years building a compound library that became its drug development... View Details
Keywords: Precision Medicine; Cancer; Biotechnology; Drug Development; Strategy; Expansion; Science; Genetics; Information Technology; Entrepreneurship; Organizational Culture; Management; Growth and Development; Pharmaceutical Industry; United States; Cambridge; Massachusetts
Citation
Educators
Purchase
Related
Hamermesh, Richard G., Kathy Giusti, and Susie L. Ma. "Breakthroughs at Blueprint Medicines." Harvard Business School Case 820-001, June 2020.
  • February 26, 2003
  • Article

Consumers' Reports on the Health Effects of Direct-To-Consumer Drug Advertising

By: Joel S. Weissman, David Blumenthal, Alvin J. Silk, Kinga Zapert, Michael Newman and Robert Leitman
Keywords: Customers; Advertising; Health; Pharmaceutical Industry
Citation
Find at Harvard
Read Now
Related
Weissman, Joel S., David Blumenthal, Alvin J. Silk, Kinga Zapert, Michael Newman, and Robert Leitman. "Consumers' Reports on the Health Effects of Direct-To-Consumer Drug Advertising." Health Affairs (February 26, 2003).
  • November 2019
  • Case

The Genesis Lab at Novartis

By: Amy C. Edmondson, Ranjay Gulati, Patrick J. Healy and Kerry Herman
Novartis' Genesis Labs program, launched in 2016 as part of Novartis Institutes for Biomedical Research (NIBR), hosted pitch competitions where teams of NIBR scientists proposed ideas to explore that aimed to revolutionize drug discovery. The goal was to break down... View Details
Keywords: Drug Discovery; Health Care and Treatment; Research and Development; Innovation and Invention; Programs; Management
Citation
Educators
Purchase
Related
Edmondson, Amy C., Ranjay Gulati, Patrick J. Healy, and Kerry Herman. "The Genesis Lab at Novartis." Harvard Business School Case 620-007, November 2019.
  • August 2020
  • Article

A History of Prescription Drug Monitoring Programs in the United States: Political Appeal and Public Health Efficacy

By: A Jay Holmgren, Alyssa Botelho and Allan M Brandt
Prescription drug monitoring programs (PDMPs) have become a widely embraced policy to address the US opioid crisis. Despite mixed scientific evidence on their effectiveness at improving health and reducing overdose deaths, 49 states and Washington, DC have adopted... View Details
Keywords: Health Disorders; Information Technology; Programs; Technology Adoption; History; Government and Politics; Policy; United States
Citation
Register to Read
Related
Holmgren, A Jay, Alyssa Botelho, and Allan M Brandt. "A History of Prescription Drug Monitoring Programs in the United States: Political Appeal and Public Health Efficacy." American Journal of Public Health 110, no. 8 (August 2020).
  • fall 1994
  • Article

Racing to Invest? The Dynamics of Competition in Ethical Drug Discovery

By: Rebecca M. Henderson and Ian Cockburn
Keywords: Investment; Competition; Ethics; Health
Citation
Read Now
Related
Henderson, Rebecca M., and Ian Cockburn. "Racing to Invest? The Dynamics of Competition in Ethical Drug Discovery." Journal of Economics & Management Strategy 3, no. 3 (fall 1994): 481–519.
  • 2001
  • Working Paper

Asset Accumulation, Interdependence and Technological Change: Evidence from Pharmaceutical Drug Discovery

By: Stefan Thomke and Walter Kuemmerle
Citation
Related
Thomke, Stefan, and Walter Kuemmerle. "Asset Accumulation, Interdependence and Technological Change: Evidence from Pharmaceutical Drug Discovery." Harvard Business School Working Paper, No. 00-086, July 2001.
  • July 2002
  • Article

Asset Accumulation, Interdependence and Technological Change: Evidence from Pharmaceutical Drug Discovery

By: Stefan Thomke and Walter Kuemmerle
Keywords: Assets; Information Technology; Change; Health
Citation
Find at Harvard
Related
Thomke, Stefan, and Walter Kuemmerle. "Asset Accumulation, Interdependence and Technological Change: Evidence from Pharmaceutical Drug Discovery." Strategic Management Journal 23, no. 7 (July 2002): 619–635.
  • February 1998 (Revised March 2003)
  • Teaching Note

Eli Lilly and Company: Drug Development Strategy (A) and (B) TN

By: Stefan H. Thomke and Ashok Nimgade
Teaching Note for (9-698-010) and (9-698-026). View Details
Citation
Purchase
Related
Thomke, Stefan H., and Ashok Nimgade. "Eli Lilly and Company: Drug Development Strategy (A) and (B) TN." Harvard Business School Teaching Note 698-033, February 1998. (Revised March 2003.)
  • January–February 2021
  • Article

Food and Drug Administration Guidance Documents and New Medical Devices: The Case of Breast Prostheses

By: Rachel E. Weitzman, Ariel Dora Stern and Daniel B. Kramer
As pressure mounts on the Food and Drug Administration (FDA) to speed its review process for novel devices, and budgetary pressures further strain its resources, the critical role of guidance documents in assuring consistent, rigorous, and scientifically grounded... View Details
Keywords: Medical Devices; FDA; Health Care and Treatment; Government Administration; Information; Standards
Citation
Read Now
Purchase
Related
Weitzman, Rachel E., Ariel Dora Stern, and Daniel B. Kramer. "Food and Drug Administration Guidance Documents and New Medical Devices: The Case of Breast Prostheses." American Journal of Therapeutics 28, no. 1 (January–February 2021).
  • Article

Absorptive Capacity, Coauthoring Behavior, and the Organization of Research in Drug Discovery

By: Rebecca M. Henderson and Iain Cockburn
Keywords: Behavior; Research and Development; Organizations; Health
Citation
Find at Harvard
Read Now
Related
Henderson, Rebecca M., and Iain Cockburn. "Absorptive Capacity, Coauthoring Behavior, and the Organization of Research in Drug Discovery." Journal of Industrial Economics 46, no. 2 (June 1998): 157–182.
  • spring 1996
  • Article

Scale, Scope and Spillovers: The Determinants of Research Productifity in Drug Discovery

By: Rebecca M. Henderson and Ian Cockburn
Keywords: Research; Product; Health
Citation
Find at Harvard
Read Now
Related
Henderson, Rebecca M., and Ian Cockburn. "Scale, Scope and Spillovers: The Determinants of Research Productifity in Drug Discovery." RAND Journal of Economics 27, no. 1 (spring 1996): 32–59.
  • 2022
  • Working Paper

Causal Inference During A Pandemic: Evidence on the Effectiveness of Nebulized Ibuprofen as an Unproven Treatment for COVID-19 in Argentina

By: Sebastian Calonico, Rafael Di Tella and Juan Cruz Lopez Del Valle
Many medical decisions during the pandemic were made without the support of causal evidence obtained in clinical trials. We study the case of nebulized ibuprofen (NaIHS), a drug that was extensively used on COVID-19 patients in Argentina amidst wild claims about its... View Details
Keywords: COVID-19; Drug Treatment; Health Pandemics; Health Care and Treatment; Decision Making; Outcome or Result; Argentina
Citation
Find at Harvard
Read Now
Related
Calonico, Sebastian, Rafael Di Tella, and Juan Cruz Lopez Del Valle. "Causal Inference During A Pandemic: Evidence on the Effectiveness of Nebulized Ibuprofen as an Unproven Treatment for COVID-19 in Argentina." NBER Working Paper Series, No. 30084, May 2022.
  • Article

Incidence and Preventability of Adverse Drug Events in the Nursing Home Setting

By: J. H. Gurwitz, T. S. Field, J. Avorn, D. McCormick, S. Jain, M. Eckler, M. Benser, A. Edmondson and D. W. Bates
Keywords: Health; Health Industry
Citation
Find at Harvard
Related
Gurwitz, J. H., T. S. Field, J. Avorn, D. McCormick, S. Jain, M. Eckler, M. Benser, A. Edmondson, and D. W. Bates. "Incidence and Preventability of Adverse Drug Events in the Nursing Home Setting." American Journal of Medicine 109, no. 2 (2000): 87–94.
  • June 2021
  • Supplement

Who Lives & Who Dies: Expanded Access for Experimental Drugs at Chimerix (B)

By: Amitabh Chandra and Spencer Lee-Rey
Citation
Purchase
Related
Chandra, Amitabh, and Spencer Lee-Rey. "Who Lives & Who Dies: Expanded Access for Experimental Drugs at Chimerix (B)." Harvard Business School Supplement 621-111, June 2021.
  • July 2010
  • Teaching Note

Metabical: Positioning and Communications Strategy for a New Weight Loss Drug (Brief Case)

By: John A. Quelch and Heather Beckham
Teaching note to case #4240. View Details
Citation
Purchase
Related
Quelch, John A., and Heather Beckham. "Metabical: Positioning and Communications Strategy for a New Weight Loss Drug (Brief Case)." Harvard Business School Teaching Note 104-241, July 2010.
  • Summer 2021
  • Article

The Cost and Evolution of Quality at Cipla Ltd, 1935–2016

By: Muhammad H. Zaman and Tarun Khanna
This article examines the evolution of Indian pharmaceutical manufacturer Cipla towards producing drugs that met the quality standards of European and U.S. regulators. It employs new research in Cipla’s corporate archives, the Creating Emerging Markets database, and... View Details
Keywords: Cipla; Pharmaceuticals; Drug Quality; Generics; Quality; Standards; Information Technology; Cost; Organizational Culture; Business History; Pharmaceutical Industry; India
Citation
Find at Harvard
Related
Zaman, Muhammad H., and Tarun Khanna. "The Cost and Evolution of Quality at Cipla Ltd, 1935–2016." Business History Review 95, no. 2 (Summer 2021): 249–274.
  • October 2021 (Revised October 2022)
  • Case

The Opioid Settlement and Controversy Over CEO Pay at AmerisourceBergen

By: Suraj Srinivasan and Li-Kuan Ni
In 2020, AmerisourceBergen Corporation, a Fortune 50 company in the drug distribution industry, agreed to settle thousands of lawsuits filed nationwide against the company for its opioid distribution practices that critics alleged had contributed to the nationwide... View Details
Keywords: Opioids; Drug; Investors; Shareholder Activism; Investment Activism; Executive Compensation; Corporate Accountability; Corporate Governance; Governance Compliance; Governance Controls; Risk Management; Corporate Social Responsibility and Impact; Business and Shareholder Relations; Business and Stakeholder Relations; Legal Liability; Distribution Industry; Health Industry; Pharmaceutical Industry; United States; West Virginia; Tennessee; Ohio; Pennsylvania
Citation
Educators
Purchase
Related
Srinivasan, Suraj, and Li-Kuan Ni. "The Opioid Settlement and Controversy Over CEO Pay at AmerisourceBergen." Harvard Business School Case 122-014, October 2021. (Revised October 2022.)
  • June 2021
  • Case

Who Lives & Who Dies: Expanded Access for Experimental Drugs at Chimerix (A)

By: Amitabh Chandra and Spencer Lee-Rey
Citation
Educators
Purchase
Related
Chandra, Amitabh, and Spencer Lee-Rey. "Who Lives & Who Dies: Expanded Access for Experimental Drugs at Chimerix (A)." Harvard Business School Case 621-110, June 2021.
  • February 2024
  • Case

Civica Rx: A Not-for-Profit Founded to Address Market Failures in the Generic Drug Industry

By: Leemore S. Dafny
Citation
Educators
Purchase
Related
Dafny, Leemore S. "Civica Rx: A Not-for-Profit Founded to Address Market Failures in the Generic Drug Industry." Harvard Business School Case 324-057, February 2024.
  • ←
  • 6
  • 7
  • …
  • 30
  • 31
  • →

Are you looking for?

→Search All HBS Web
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College.